Cardio Vascular DiseaseASANDENCT07427355
African Studies on Aging and Noncommunicable Diseases Epidemiology
An observational study of Cardio Vascular Disease and Cardiovascular, run by Alliance For Medical Research in Africa at 1 site in Senegal.
Trial summary
Despite the rising burden of noncommunicable diseases (NCDs), including cardiovascular diseases (CVDs), across Africa, high-quality evidence on the distribution of NCDs and their risk factors remains strikingly scarce. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardio Vascular Disease, Cardiovascular, Cancer
- How many people
- 1,000,000 participants
- Where
- 1 siteSenegal
- Study dates
- 15 Jan 2025to Jun 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The ASANDE platform integrates harmonised individual-level data from more than 1 million participants across over 100 countries and six continents, derived from nationally representative cross-sectional surveys and population-based longitudinal cohort studies. Participating studies are organised into major geographical region: Asia; Eastern Europe; North Africa and the Middle East; North and Latin America; Sub-Saharan Africa; and Western Europe, thereby facilitating rigorous regional and inter-regional comparisons. The harmonised dataset provides standardised and comparable information on major noncommunicable disease (NCD) risk factors, including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking status, and diabetes mellitus, together with data on major NCD outcomes, including cardiovascular diseases, cancer, chronic respiratory diseases, and cause-specific mortality.
- Inclusion criteria
We included cross-sectional surveys and longitudinal population-based studies providing individual-level data on established noncommunicable disease (NCD) risk factors, including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking status, and diabetes mellitus, together with information on predefined NCD outcomes of interest (including cardiovascular diseases, cancer, chronic respiratory diseases, and other major NCDs). For longitudinal studies, prospective ascertainment of incident events and mortality was required.
- Exclusion criteria
Participants were excluded if they were younger than 18 years at the time of assessment, had missing data on the outcome of interest, had no available information on the exposure variables (NCD risk factors), or, for longitudinal analyses, had a documented history of the respective NCD outcome at baseline.
Trial locations and contacts
1 site in 1 country.
Senegal1 site
Institut Pasteur de Dakar; Address: 36, Avenue Pasteur, B.P. 220 - Dakar, Senegal
Dakar
About this study
Despite the rising burden of noncommunicable diseases (NCDs), including cardiovascular diseases (CVDs), across Africa, high-quality evidence on the distribution of NCDs and their risk factors remains strikingly scarce. Many global estimates continue to rely on limited empirical data from African countries, and this persistent data gap has led major international research collaborations to underrepresent the continent. This reality highlights an urgent need for granular, context-specific, and methodologically robust data on NCDs and their determinants across Africa.
The African Studies on Ageing and Noncommunicable Disease Epidemiology (ASANDE) initiative responds directly to this need by assembling harmonized, individual-level datasets from African populations, complemented by comparable data from other global regions. With recruitment underway, ASANDE seeks to quantify and compare the associations between major NCD risk factors, including cardiometabolic, behavioral, and environmental determinants, and the incidence and mortality of major NCD outcomes (cardiovascular diseases, cancer, chronic respiratory diseases, diabetes, and other NCDs) across world regions, with a particular emphasis on disparities between African populations and the rest of the global population.
- Conditions
- Cardio Vascular Disease, Cardiovascular, Cancer, Mortality
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
non communicable diseases
Event rates of noncommunicable diseases (NCDs) and NCD subtypes: First fatal or non-fatal diagnosis of cardiovascular diseases (including myocardial infarction, unstable angina, coronary revascularization, ischemic or hemorrhagic stroke), cancer, chronic respiratory diseases (including chronic obstructive pulmonary disease and asthma), type 2 diabetes mellitus, chronic kidney disease, or other major NCD-related outcomes, as well as NCD-related or unclassifiable death. The type of outcome measurement varies across cohorts. NCD cases and subtypes are assessed through self-reported questionnaire information, clinical examinations, medical record validation, national hospital discharge registry data, disease-specific registries (e.g., cancer registries), causes of death registry data, or central death registries, depending on the study protocol of the respective cohort studies.
Measured: Median follow-up of approximately 10 years across cohorts.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2026
- Study start15 Jan 2025
- Primary completionJul 2026 (estimated)
- Study completionJun 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cardio Vascular DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alliance For Medical Research in Africa
- Sponsor type
- Research network
- Collaborators
- Institut Pasteur de Dakar
- Responsible party
- Principal investigator, Bamba Gaye, Alliance For Medical Research in Africa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07427355
- Sponsor's protocol ID
- ASANDE001
- Acronym
- ASANDE
- Status last verified
- Feb 2026
- First submitted
- 16 Feb 2026
- Last updated
- 23 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Gaye B, Singh G, Sattler ELP, Morsy MI, Abdelnoor A, Aguayo L, Carter J, Clarke RJ, Dieng S, Diop HB, Dzudie A, Edjimbi J, Gary-Webb TL, Gaye ND, Guzik B, Guzik TJ, Jalloh MB, Ka MM, Lam H, Lassale C, Lewington S, Marijon E, Marsh K, Ntusi NAB, Okitondo CD, Sekitoleko I, Sow PS, Tajeu GS, Jobe M, Lorenz T, Maffia P, Fall IS; ASANDE Consortium collaborators. Global inequalities in cardiometabolic care and achievable cardiovascular risk reduction by wealth, region, and sex: a pooled analysis of individual participant data from 76 countries. Lancet Glob Health. 2026 Sep 17:104082. doi: 10.1016/j.langlo.2026.104082. Online ahead of print.
PubMed 42753774
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- African Studies on Aging and Noncommunicable Diseases Epidemiology
- ClinicalTrials.gov ID
- NCT07427355
- Acronym / sponsor ID
- ASANDE / ASANDE001
- Conditions
- Cardio Vascular Disease, Cardiovascular, Cancer, Mortality
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,000,000 participants (estimated)
- Lead sponsor
- Alliance For Medical Research in AfricaResearch network
- Collaborators
- Institut Pasteur de Dakar
- Study start
- 15 Jan 2025 (actual)
- Primary completion
- Jul 2026 (estimated)
- Study completion
- Jun 2030 (estimated)
- First posted
- 23 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Despite the rising burden of noncommunicable diseases (NCDs), including cardiovascular diseases (CVDs), across Africa, high-quality evidence on the distribution of NCDs and their risk factors remains strikingly scarce. Many global estimates continue to rely on limited empirical data from African countries, and this persistent data gap has led major international research collaborations to underrepresent the continent. This reality highlights an urgent need for granular, context-specific, and methodologically robust data on NCDs and their determinants across Africa.
The African Studies on Ageing and Noncommunicable Disease Epidemiology (ASANDE) initiative responds directly to this need by assembling harmonized, individual-level datasets from African populations, complemented by comparable data from other global regions. With recruitment underway, ASANDE seeks to quantify and compare the associations between major NCD risk factors, including cardiometabolic, behavioral, and environmental determinants, and the incidence and mortality of major NCD outcomes (cardiovascular diseases, cancer, chronic respiratory diseases, diabetes, and other NCDs) across world regions, with a particular emphasis on disparities between African populations and the rest of the global population.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The ASANDE platform integrates harmonised individual-level data from more than 1 million participants across over 100 countries and six continents, derived from nationally representative cross-sectional surveys and population-based longitudinal cohort studies. Participating studies are organised into major geographical region: Asia; Eastern Europe; North Africa and the Middle East; North and Latin America; Sub-Saharan Africa; and Western Europe, thereby facilitating rigorous regional and inter-regional comparisons. The harmonised dataset provides standardised and comparable information on major noncommunicable disease (NCD) risk factors, including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking status, and diabetes mellitus, together with data on major NCD outcomes, including cardiovascular diseases, cancer, chronic respiratory diseases, and cause-specific mortality.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
non communicable diseases
Time frame: Median follow-up of approximately 10 years across cohorts.
Event rates of noncommunicable diseases (NCDs) and NCD subtypes: First fatal or non-fatal diagnosis of cardiovascular diseases (including myocardial infarction, unstable angina, coronary revascularization, ischemic or hemorrhagic stroke), cancer, chronic respiratory diseases (including chronic obstructive pulmonary disease and asthma), type 2 diabetes mellitus, chronic kidney disease, or other major NCD-related outcomes, as well as NCD-related or unclassifiable death. The type of outcome measurement varies across cohorts. NCD cases and subtypes are assessed through self-reported questionnaire information, clinical examinations, medical record validation, national hospital discharge registry data, disease-specific registries (e.g., cancer registries), causes of death registry data, or central death registries, depending on the study protocol of the respective cohort studies.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2026.
- Derived from this study: PubMed 42753774Gaye B, Singh G, Sattler ELP, Morsy MI, Abdelnoor A, Aguayo L, Carter J, Clarke RJ, Dieng S, Diop HB, Dzudie A, Edjimbi J, Gary-Webb TL, Gaye ND, Guzik B, Guzik TJ, Jalloh MB, Ka MM, Lam H, Lassale C, Lewington S, Marijon E, Marsh K, Ntusi NAB, Okitondo CD, Sekitoleko I, Sow PS, Tajeu GS, Jobe M, Lorenz T, Maffia P, Fall IS; ASANDE Consortium collaborators. Global inequalities in cardiometabolic care and achievable cardiovascular risk reduction by wealth, region, and sex: a pooled analysis of individual participant data from 76 countries. Lancet Glob Health. 2026 Sep 17:104082. doi: 10.1016/j.langlo.2026.104082. Online ahead of print.
Related trials for Cardio Vascular Disease
Not yet recruiting
Community Health Worker Nutrition Self-Management Support for Cardio-Kidney-Metabolic Health
Hypertension (HTN), CKD - Chronic Kidney Disease
Not yet recruitingPhase 4
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA
Not yet recruitingObservational study
Hemodynamic Evaluation of Left Atrial Pressure in Relationship to Pulmonary Capillary Wedge Pressure in Cardio Thoracic Patients
Cardiogenic Shock, Pulmonary Edema Cardiac Cause
Recruiting
Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study
Systemic Lupus Erythematosus, Atherosclerosis Generalized
Not yet recruitingObservational study
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Heart Failure, Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardio Vascular Disease and Cardiovascular, run by Alliance For Medical Research in Africa at 1 site in Senegal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Senegal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
non communicable diseases (time frame: Median follow-up of approximately 10 years across cohorts.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07427355, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2026.